Do analysts prefer SNGX or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SNGX or SLXN more profitable?

Soligenix's return on equity of -180.25% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -180.25% -107.46% Silexion Therapeutics N/A -563.11% -201.73%

Do analysts prefer ENLV or SLXN?

Enlivex Therapeutics presently has a consensus price target of $247.50, suggesting a potential upside of 111,185.97%. Given Enlivex Therapeutics' higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Silexion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, ENLV or SLXN?

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Silexion Therapeutics N/A N/A -$11.91M -$42.47 N/A

Is ENLV or SLXN more profitable?

Enlivex Therapeutics' return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A N/A N/A Silexion Therapeutics N/A -563.11% -201.73%

Do analysts recommend LIMN or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, LIMN or SLXN?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A Silexion Therapeutics N/A N/A -$11.91M -$42.47 N/A

Is LIMN or SLXN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Silexion Therapeutics N/A -563.11% -201.73%

Do analysts recommend SLXN or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, SLXN or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silexion Therapeutics N/A N/A -$11.91M -$42.47 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is SLXN or LNAI more profitable?

Lunai Bioworks' return on equity of 0.00% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silexion Therapeutics N/A -563.11% -201.73% Lunai Bioworks N/A N/A -1,617.76%

Does the media refer more to SLXN or LNAI?

In the previous week, Silexion Therapeutics and Silexion Therapeutics both had 4 articles in the media. Silexion Therapeutics' average media sentiment score of 0.90 beat Lunai Bioworks' score of 0.61 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lunai Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SLXN or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Silexion Therapeutics (SLXN) Competitors

$0.17 -0.01 (-5.68%)

As of 01:48 PM Eastern

Compare

SLXN vs. SNGX, ENLV, LIMN, LNAI, and XBIO

Should you buy Silexion Therapeutics stock or one of its competitors? Silexion Therapeutics's main competitors and comparable companies include Soligenix (SNGX), Enlivex Therapeutics (ENLV), Liminatus Pharma (LIMN), Lunai Bioworks (LNAI), and Xenetic Biosciences (XBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silexion Therapeutics compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Soligenix's return on equity of -180.25% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-180.25%	-107.46%
Silexion Therapeutics	N/A	-563.11%	-201.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Soligenix has higher revenue and earnings than Silexion Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	$120K	41.35	-$11.08M	-$0.98	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A

3.6% of Soligenix shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 1.9% of Soligenix shares are held by company insiders. Comparatively, 0.3% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Soligenix has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 3 more articles in the media than Soligenix. MarketBeat recorded 4 mentions for Silexion Therapeutics and 1 mentions for Soligenix. Soligenix's average media sentiment score of 1.82 beat Silexion Therapeutics' score of 0.90 indicating that Soligenix is being referred to more favorably in the media.

Company	Overall Sentiment
Soligenix	Very Positive
Silexion Therapeutics	Positive

Summary

Soligenix beats Silexion Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Silexion Therapeutics compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Enlivex Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market.

In the previous week, Silexion Therapeutics had 2 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 4 mentions for Silexion Therapeutics and 2 mentions for Enlivex Therapeutics. Silexion Therapeutics' average media sentiment score of 0.90 beat Enlivex Therapeutics' score of 0.41 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Silexion Therapeutics	Positive

Enlivex Therapeutics presently has a consensus price target of $247.50, suggesting a potential upside of 111,185.97%. Given Enlivex Therapeutics' higher possible upside, research analysts clearly believe Enlivex Therapeutics is more favorable than Silexion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	N/A	N/A
Silexion Therapeutics	N/A	-563.11%	-201.73%

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 0.3% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Enlivex Therapeutics beats Silexion Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Silexion Therapeutics compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Liminatus Pharma is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A

In the previous week, Silexion Therapeutics had 3 more articles in the media than Liminatus Pharma. MarketBeat recorded 4 mentions for Silexion Therapeutics and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.79 beat Silexion Therapeutics' score of 0.90 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Very Positive
Silexion Therapeutics	Positive

Liminatus Pharma has a beta of 4.97, suggesting that its share price is 397% more volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

11.0% of Silexion Therapeutics shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by insiders. Comparatively, 0.3% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liminatus Pharma's return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Silexion Therapeutics	N/A	-563.11%	-201.73%

Summary

Liminatus Pharma beats Silexion Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Silexion Therapeutics compare to Lunai Bioworks?

Silexion Therapeutics (NASDAQ:SLXN) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

In the previous week, Silexion Therapeutics and Silexion Therapeutics both had 4 articles in the media. Silexion Therapeutics' average media sentiment score of 0.90 beat Lunai Bioworks' score of 0.61 indicating that Silexion Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silexion Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lunai Bioworks' return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Lunai Bioworks	N/A	N/A	-1,617.76%

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 0.3% of Silexion Therapeutics shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Silexion Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Summary

Silexion Therapeutics and Lunai Bioworks tied by winning 5 of the 10 factors compared between the two stocks.

How does Silexion Therapeutics compare to Xenetic Biosciences?

Silexion Therapeutics (NASDAQ:SLXN) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Silexion Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Xenetic Biosciences' return on equity of -40.62% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	-563.11%	-201.73%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 0.3% of Silexion Therapeutics shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Xenetic Biosciences has higher revenue and earnings than Silexion Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A
Xenetic Biosciences	$2.98M	1.61	-$2.68M	-$1.16	N/A

Silexion Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

In the previous week, Silexion Therapeutics had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Silexion Therapeutics and 2 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.39 beat Silexion Therapeutics' score of 0.90 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silexion Therapeutics	Positive
Xenetic Biosciences	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Xenetic Biosciences beats Silexion Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Silexion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLXN vs. The Competition

Export

Metric	Silexion Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$917K	$3.89B	$7.27B	$12.97B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	0.00	12.96	275.40	25.37
Price / Sales	N/A	1,150.23	562.29	78.82
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.02	16.59	10.55	5.95
Net Income	-$11.91M	-$22.65M	$3.50B	$380.75M
7 Day Performance	-34.54%	-6.11%	-3.92%	-3.96%
1 Month Performance	-56.93%	-13.89%	-8.30%	-6.81%
1 Year Performance	-99.56%	6.58%	2.35%	-4.58%

Silexion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLXN Silexion Therapeutics	1.3154 of 5 stars	$0.17 -5.7%	N/A	-99.5%	$917K	N/A	N/A	14	Gap Up
SNGX Soligenix	1.2536 of 5 stars	$0.36 +0.6%	N/A	-80.5%	$5.34M	$120K	N/A	14
ENLV Enlivex Therapeutics	2.5372 of 5 stars	$0.30 -11.2%	$247.50 +81,853.6%	-98.7%	$5.28M	N/A	N/A	34	Short Interest Increase Gap Up High Trading Volume
LIMN Liminatus Pharma	0.9497 of 5 stars	$3.83 +3.5%	N/A	-95.2%	$5.14M	N/A	N/A	1
LNAI Lunai Bioworks	0.3994 of 5 stars	$1.11 -1.9%	N/A	-88.9%	$5.02M	N/A	N/A	29	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLXN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silexion Therapeutics (SLXN) Competitors

SLXN vs. SNGX, ENLV, LIMN, LNAI, and XBIO

How does Silexion Therapeutics compare to Soligenix?

Summary

How does Silexion Therapeutics compare to Enlivex Therapeutics?

Summary

How does Silexion Therapeutics compare to Liminatus Pharma?

Summary

How does Silexion Therapeutics compare to Lunai Bioworks?

Summary

How does Silexion Therapeutics compare to Xenetic Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silexion Therapeutics (SLXN) Competitors

SLXN vs. SNGX, ENLV, LIMN, LNAI, and XBIO

How does Silexion Therapeutics compare to Soligenix?

Is SNGX or SLXN more profitable?

Do analysts prefer SNGX or SLXN?

Which has better valuation & earnings, SNGX or SLXN?

Do institutionals and insiders hold more shares of SNGX or SLXN?

Which has more risk and volatility, SNGX or SLXN?

Does the media prefer SNGX or SLXN?

Summary

How does Silexion Therapeutics compare to Enlivex Therapeutics?

Which has more volatility and risk, ENLV or SLXN?

Does the media favor ENLV or SLXN?

Do analysts prefer ENLV or SLXN?

Is ENLV or SLXN more profitable?

Which has preferable earnings and valuation, ENLV or SLXN?

Do institutionals & insiders hold more shares of ENLV or SLXN?

Summary

How does Silexion Therapeutics compare to Liminatus Pharma?

Do analysts recommend LIMN or SLXN?

Which has preferable valuation and earnings, LIMN or SLXN?

Does the media prefer LIMN or SLXN?

Which has more volatility and risk, LIMN or SLXN?

Do institutionals and insiders believe in LIMN or SLXN?

Is LIMN or SLXN more profitable?

Summary

How does Silexion Therapeutics compare to Lunai Bioworks?

Which has preferable earnings & valuation, SLXN or LNAI?

Does the media refer more to SLXN or LNAI?

Is SLXN or LNAI more profitable?

Do institutionals & insiders hold more shares of SLXN or LNAI?

Do analysts recommend SLXN or LNAI?

Which has more volatility & risk, SLXN or LNAI?

Summary

How does Silexion Therapeutics compare to Xenetic Biosciences?

Is SLXN or XBIO more profitable?

Do institutionals and insiders hold more shares of SLXN or XBIO?

Which has stronger valuation & earnings, SLXN or XBIO?

Which has more risk and volatility, SLXN or XBIO?

Does the media refer more to SLXN or XBIO?

Do analysts recommend SLXN or XBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN vs. The Competition

Silexion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools